Tag: gastroparesis drugs global market

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Gastroparesis Drugs Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?

The gastroparesis drugs market has experienced substantial growth in recent years. It is forecast to increase from $5.7 billion in 2025 to $6.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. The market’s historical expansion can be attributed to several factors: an uptick in the diagnosis of diabetic gastroparesis, the continued application of prokinetic and antiemetic drugs, a rising prevalence of diabetes-related gastrointestinal disorders, the availability of both OTC and prescription medications for symptom relief, and the expansion of gastroenterology care services.

The gastroparesis drugs market is anticipated to experience robust expansion over the coming years. This market is projected to reach $7.37 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. Factors driving this growth during the forecast timeframe include an increase in global diabetes prevalence, heightened understanding of gastroparesis as a chronic illness, a rising need for efficacious long-term symptom management, broader availability of specialized gastrointestinal treatment, and a continuous requirement for better motility-enhancing treatments. Key trends anticipated during this period encompass an increasing dependence on prokinetic medications for symptom relief, a surge in the adoption of combination drug therapies for gastroparesis, a heightened demand for prescription-only gastroparesis medications, an expansion of treatment strategies centered on symptoms, and more widespread application of oral drug forms for extended management.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=64329955&type=smp&name=Gastroparesis%20Drugs%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Gastroparesis Drugs Market Expansion Drivers: What’s Shaping Future Growth?

The expanding occurrence of diabetes is projected to fuel the expansion of the gastroparesis drugs market in the future. Diabetes is a long-term metabolic condition marked by high blood sugar levels, stemming from either inadequate insulin generation or inefficient insulin use. The rise in diabetes cases can be attributed to factors such as inactive lifestyles, poor eating habits, genetic factors, increased urbanization, an aging populace, and increasing obesity. The gastroparesis drugs market contributes to diabetes care through medicines that alleviate symptoms like nausea, vomiting, and delayed stomach emptying, which are frequent gastrointestinal issues linked to diabetic gastroparesis. For instance, data from March 2024 by the Office for Health Improvement & Disparities, a UK-based government department, showed that from March 2022 to March 2023, the number of individuals with type 1 diabetes getting all eight suggested care processes grew by 22%, while type 2 diabetes patients experienced a 21% rise, and the proportion reaching target HbA1c levels climbed to 37.9%, marking the highest figure ever recorded by the National Diabetes Audit. Consequently, the growing incidence of diabetes is propelling the expansion of the gastroparesis drugs market.

Gastroparesis Drugs Market Segment Analysis And Revenue Potential

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Gastroparesis Drugs Market Strategic Trends: What Defines The Next Growth Phase?

Leading companies within the gastroparesis drugs market are focusing on developing innovative solutions, including novel prokinetic therapies, to enhance gastric motility and reduce associated symptoms. These novel prokinetic therapies are new medications formulated to stimulate and improve the natural movement of the stomach and intestines, aiding in more effective food passage. For instance, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for the filing of its New Drug Application (NDA) concerning tradipitant for addressing the symptoms of gastroparesis. This approval is for tradipitant, an investigational oral neurokinin-1 receptor antagonist, designated for treating gastroparesis, a significant digestive disorder with considerable unmet medical requirements. This acceptance marks a crucial regulatory achievement for Vanda as the company proceeds with seeking marketing authorization for tradipitant among gastroparesis patients.

Gastroparesis Drugs Market Key Players Shaping Industry Direction

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

View The Full Gastroparesis Drugs Market Report:

https://thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Gastroparesis Drugs Market Regional Analysis And Top Geography

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Gastroparesis Drugs Market Forecast Highlighting Growth From $6.02 Billion To $7.36 Billion

The gastroparesis drugs market has experienced robust expansion over recent years. Projections indicate a rise from $5.7 billion in 2025 to $6.02 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.7%. This historical growth has been driven by factors such as a higher number of diabetic gastroparesis diagnoses, the prolonged use of prokinetic and antiemetic agents, an increase in gastrointestinal disorders linked to diabetes, the availability of both over-the-counter and prescription symptom management options, and a broader reach of gastroenterology healthcare services.

The market for gastroparesis medications is projected to experience substantial expansion over the coming years. By 2030, its value is anticipated to reach $7.37 billion, reflecting a compound annual growth rate (CAGR) of 5.2%. This anticipated growth during the forecast period is driven by several key factors: the increasing global incidence of diabetes, a heightened recognition of gastroparesis as a persistent medical issue, a growing need for reliable solutions that deliver sustained symptom relief, enhanced availability of specialized gastrointestinal healthcare services, and the persistent demand for more effective therapies that improve gastric motility. Among the notable developments shaping this forecast period are a stronger dependence on prokinetic drugs to manage symptoms, a higher adoption of combined drug regimens specifically for gastroparesis, an increase in treatments requiring a prescription, the evolution of therapeutic strategies focused more directly on symptom alleviation, and the wider use of oral medications intended for extended care management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Gastroparesis Drugs Market Expansion Supported By Key Demand Factors

The rising incidence of diabetes is anticipated to drive expansion in the gastroparesis drugs market moving forward. Diabetes is a chronic metabolic condition marked by high blood glucose levels due to insufficient insulin production or ineffective insulin use. Its prevalence is climbing because of sedentary lifestyles, poor dietary habits, genetic factors, urbanization, aging populations, and increasing obesity rates. The gastroparesis drugs market aids diabetes management by offering medications that alleviate symptoms like nausea, vomiting, and delayed gastric emptying—common gastrointestinal issues linked to diabetic gastroparesis. For example, in March 2024, the Office for Health Improvement & Disparities, a UK government agency, reported that from March 2022 to March 2023, the number of type 1 diabetes patients receiving all eight recommended care processes grew by 22%, type 2 diabetes patients saw a 21% rise, and the proportion achieving target HbA1c levels reached 37.9%, the highest ever recorded by the National Diabetes Audit. Consequently, the growing prevalence of diabetes is fueling the gastroparesis drugs market’s growth.

Gastroparesis Drugs Market Categorization By Product Type And Application

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Gastroparesis Drugs Market Growth Trends Influencing Competitive Dynamics

Key players in the gastroparesis drugs market are actively developing advanced treatments, including novel prokinetic therapies aimed at improving gastric motility and alleviating symptoms. These therapies, which are newly formulated medications, work by stimulating and enhancing the natural movement of the stomach and intestines to facilitate more efficient food passage. For example, in December 2023, Vanda Pharmaceuticals Inc., a biopharmaceutical company based in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for the submission of its New Drug Application (NDA) for tradipitant to address gastroparesis symptoms. This approval specifically pertains to tradipitant, an investigational oral neurokinin-1 receptor antagonist designed to treat gastroparesis, a severe digestive disorder for which existing treatment options are limited. This acceptance represents a crucial regulatory achievement for Vanda as it moves forward in seeking marketing authorization for tradipitant among patients suffering from gastroparesis.

Gastroparesis Drugs Market Company Landscape And Strategic Competition

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

Access The Complete Gastroparesis Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Gastroparesis Drugs Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Gastroparesis Drugs Market Over The Forecast Period?

The gastroparesis drugs market has shown robust expansion in recent years. It is anticipated to increase from $5.7 billion in 2025 to $6.02 billion in 2026, registering a compound annual growth rate (CAGR) of 5.7%. The historical growth in this market can be linked to factors such as the heightened diagnosis of diabetic gastroparesis, the enduring usage of prokinetic and antiemetic drugs, the rising incidence of diabetes-related gastrointestinal disorders, the accessibility of both over-the-counter and prescription symptom relief medications, and the expansion of gastroenterology care services.

The gastroparesis drugs market is projected to experience substantial expansion in the upcoming years, with its size anticipated to reach $7.37 billion in 2030, growing at a compound annual growth rate (CAGR) of 5.2%. This expected growth throughout the forecast period is driven by factors such as the increasing global incidence of diabetes, a rising awareness of gastroparesis as a chronic condition, a heightened demand for effective long-term symptom management, improved access to specialty gastrointestinal care, and an ongoing need for better therapies to enhance motility. Key trends during this period are set to include a greater reliance on prokinetic agents for symptom control, an increased adoption of combination drug therapy for gastroparesis, a growing demand for prescription-based gastroparesis treatments, the broadening of symptom-focused treatment approaches, and a more extensive use of oral drug formulations for long-term management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

What Major Growth Factors Are Impacting The Gastroparesis Drugs Market?

The increasing occurrence of diabetes is anticipated to drive the expansion of the gastroparesis drugs market moving forward. Diabetes is a chronic metabolic condition defined by elevated blood sugar levels, resulting from insufficient insulin generation or ineffective insulin utilization. The prevalence of diabetes is escalating due to factors such as sedentary lifestyles, unhealthy dietary practices, genetic predispositions, urbanization, an aging demographic, and rising obesity rates. The gastroparesis drugs market supports diabetes care by supplying medications that alleviate symptoms like nausea, vomiting, and delayed gastric emptying, which are common gastrointestinal complications associated with diabetic gastroparesis. For instance, in March 2024, information from the Office for Health Improvement & Disparities, a UK-based government department, revealed that between March 2022 and March 2023, the number of individuals with type 1 diabetes receiving all eight recommended care processes saw a 22% increase, while type 2 diabetes patients experienced a 21% rise, and the percentage reaching target HbA1c levels climbed to 37.9%, which was the highest value ever reported by the National Diabetes Audit. Thus, the growing prevalence of diabetes is stimulating the growth of the gastroparesis drugs market.

What Are The Major Segment Categories Within The Gastroparesis Drugs Market?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

What Trends Are Shaping The Gastroparesis Drugs Market Structure?

Leading firms within the gastroparesis drugs market are concentrating on creating cutting-edge remedies, including new prokinetic treatments, to enhance stomach movement and alleviate associated symptoms. These novel prokinetic therapies represent fresh pharmaceutical approaches intended to stimulate and improve the natural propulsion of the stomach and bowels, thereby facilitating more efficient food transit. As an illustration, in December 2023, Vanda Pharmaceuticals Inc., a biopharmaceutical firm based in the US, secured approval from the U.S. Food and Drug Administration (FDA) to proceed with its New Drug Application (NDA) for tradipitant, aimed at managing gastroparesis symptoms. This acceptance pertains to tradipitant, an experimental oral neurokinin-1 receptor antagonist, designated for addressing gastroparesis, a severe digestive condition characterized by significant unaddressed medical requirements. Such approval signifies a crucial regulatory achievement for Vanda as the company persists in seeking market authorization for tradipitant for individuals suffering from gastroparesis.

Who Are The Prominent Players Across The Gastroparesis Drugs Market?

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

Access The Complete Gastroparesis Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Which Region Has The Strongest Presence In The Gastroparesis Drugs Market?

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Gastroparesis Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Browse Through More Reports Similar to the Global Gastroparesis Drugs Market 2026, By The Business Research Company

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Gastroparesis Drugs Market Over The 2026–2030 Period?

The gastroparesis drugs market size has shown robust growth over recent years. It is forecasted to increase from $5.7 billion in 2025 to $6.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. This historic growth can be attributed to several factors, including the increasing diagnosis of diabetic gastroparesis, the established use of prokinetic and antiemetic drugs, the rising prevalence of diabetes-related gastrointestinal disorders, the availability of both over-the-counter and prescription medications for symptom relief, and the expansion of gastroenterology care services.

The gastroparesis drugs market is projected to experience substantial expansion over the coming years. By 2030, its valuation is anticipated to reach $7.37 billion, demonstrating a compound annual growth rate (CAGR) of 5.2%. This projected growth during the forecast period is driven by several factors, including the increasing global prevalence of diabetes, heightened recognition of gastroparesis as a chronic ailment, a greater need for effective long-term symptom management, broader availability of specialized gastrointestinal care, and the continuous requirement for enhanced motility-boosting treatments. Key developments expected in this period encompass an escalating dependence on prokinetic agents for managing symptoms, a rise in the application of combination drug therapies for gastroparesis, increasing requests for prescription-only gastroparesis medications, the proliferation of symptom-targeted treatment methodologies, and more widespread adoption of oral drug formulations for ongoing management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Key Drivers Are Affecting The Gastroparesis Drugs Market Development?

The rising incidence of diabetes is projected to fuel the expansion of the gastroparesis drugs market in the coming years. This condition is a long-term metabolic ailment marked by high blood glucose levels, which stem from either inadequate insulin generation or inefficient insulin use. Several factors contribute to the increasing occurrence of diabetes, including inactive lifestyles, poor eating habits, genetic susceptibility, urbanization, an aging demographic, and expanding obesity figures. The gastroparesis drugs market plays a role in diabetes management by offering medicines that alleviate symptoms like nausea, vomiting, and slow stomach emptying, which are frequent digestive issues linked with diabetic gastroparesis. For example, data released in March 2024 by the Office for Health Improvement & Disparities, a UK-based government department, indicated that from March 2022 to March 2023, the number of individuals with type 1 diabetes receiving all eight recommended care processes experienced a 22% rise. Concurrently, type 2 diabetes patients showed a 21% increase, and the proportion reaching target HbA1c levels climbed to 37.9%, representing the highest figure ever recorded by the National Diabetes Audit. Consequently, the growing incidence of diabetes is propelling the expansion of the gastroparesis drugs market.

How Are Segments Identified Within The Gastroparesis Drugs Market Segment Framework?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Which Trends Are Shaping Growth In The Gastroparesis Drugs Market?

Leading companies within the gastroparesis drugs market are concentrating on creating advanced solutions, including new prokinetic therapies, to enhance gastric motility and alleviate related symptoms. These novel prokinetic therapies represent fresh medications engineered to stimulate and boost the natural movement of the stomach and intestines, facilitating more efficient food passage. For example, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for the submission of Vanda’s New Drug Application (NDA) for tradipitant, intended for the management of gastroparesis symptoms. This specific approval concerns tradipitant, an investigational oral neurokinin-1 receptor antagonist, for addressing gastroparesis, which is a severe digestive ailment with significant unmet medical necessities. This acceptance represents a pivotal regulatory achievement for Vanda as the company proceeds with its efforts to gain marketing authorization for tradipitant in patients with gastroparesis.

Who Are The Companies Competing Within The Gastroparesis Drugs Market?

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

Get The Full Gastroparesis Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Which Region Is The Leading Market For The Gastroparesis Drugs Market?

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gastroparesis Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Browse Through More Reports Similar to the Global Gastroparesis Drugs Market 2026, By The Business Research Company

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Gastroparesis Drugs Market Over The 2026–2030 Period?

The gastroparesis drugs market size has shown robust growth over recent years. It is forecasted to increase from $5.7 billion in 2025 to $6.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. This historic growth can be attributed to several factors, including the increasing diagnosis of diabetic gastroparesis, the established use of prokinetic and antiemetic drugs, the rising prevalence of diabetes-related gastrointestinal disorders, the availability of both over-the-counter and prescription medications for symptom relief, and the expansion of gastroenterology care services.

The gastroparesis drugs market is projected to experience substantial expansion over the coming years. By 2030, its valuation is anticipated to reach $7.37 billion, demonstrating a compound annual growth rate (CAGR) of 5.2%. This projected growth during the forecast period is driven by several factors, including the increasing global prevalence of diabetes, heightened recognition of gastroparesis as a chronic ailment, a greater need for effective long-term symptom management, broader availability of specialized gastrointestinal care, and the continuous requirement for enhanced motility-boosting treatments. Key developments expected in this period encompass an escalating dependence on prokinetic agents for managing symptoms, a rise in the application of combination drug therapies for gastroparesis, increasing requests for prescription-only gastroparesis medications, the proliferation of symptom-targeted treatment methodologies, and more widespread adoption of oral drug formulations for ongoing management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Key Drivers Are Affecting The Gastroparesis Drugs Market Development?

The rising incidence of diabetes is projected to fuel the expansion of the gastroparesis drugs market in the coming years. This condition is a long-term metabolic ailment marked by high blood glucose levels, which stem from either inadequate insulin generation or inefficient insulin use. Several factors contribute to the increasing occurrence of diabetes, including inactive lifestyles, poor eating habits, genetic susceptibility, urbanization, an aging demographic, and expanding obesity figures. The gastroparesis drugs market plays a role in diabetes management by offering medicines that alleviate symptoms like nausea, vomiting, and slow stomach emptying, which are frequent digestive issues linked with diabetic gastroparesis. For example, data released in March 2024 by the Office for Health Improvement & Disparities, a UK-based government department, indicated that from March 2022 to March 2023, the number of individuals with type 1 diabetes receiving all eight recommended care processes experienced a 22% rise. Concurrently, type 2 diabetes patients showed a 21% increase, and the proportion reaching target HbA1c levels climbed to 37.9%, representing the highest figure ever recorded by the National Diabetes Audit. Consequently, the growing incidence of diabetes is propelling the expansion of the gastroparesis drugs market.

How Are Segments Identified Within The Gastroparesis Drugs Market Segment Framework?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Which Trends Are Shaping Growth In The Gastroparesis Drugs Market?

Leading companies within the gastroparesis drugs market are concentrating on creating advanced solutions, including new prokinetic therapies, to enhance gastric motility and alleviate related symptoms. These novel prokinetic therapies represent fresh medications engineered to stimulate and boost the natural movement of the stomach and intestines, facilitating more efficient food passage. For example, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for the submission of Vanda’s New Drug Application (NDA) for tradipitant, intended for the management of gastroparesis symptoms. This specific approval concerns tradipitant, an investigational oral neurokinin-1 receptor antagonist, for addressing gastroparesis, which is a severe digestive ailment with significant unmet medical necessities. This acceptance represents a pivotal regulatory achievement for Vanda as the company proceeds with its efforts to gain marketing authorization for tradipitant in patients with gastroparesis.

Who Are The Companies Competing Within The Gastroparesis Drugs Market?

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

Get The Full Gastroparesis Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Which Region Is The Leading Market For The Gastroparesis Drugs Market?

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gastroparesis Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Browse Through More Reports Similar to the Global Gastroparesis Drugs Market 2026, By The Business Research Company

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Gastroparesis Drugs Market Over The 2026–2030 Period?

The gastroparesis drugs market size has shown robust growth over recent years. It is forecasted to increase from $5.7 billion in 2025 to $6.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. This historic growth can be attributed to several factors, including the increasing diagnosis of diabetic gastroparesis, the established use of prokinetic and antiemetic drugs, the rising prevalence of diabetes-related gastrointestinal disorders, the availability of both over-the-counter and prescription medications for symptom relief, and the expansion of gastroenterology care services.

The gastroparesis drugs market is projected to experience substantial expansion over the coming years. By 2030, its valuation is anticipated to reach $7.37 billion, demonstrating a compound annual growth rate (CAGR) of 5.2%. This projected growth during the forecast period is driven by several factors, including the increasing global prevalence of diabetes, heightened recognition of gastroparesis as a chronic ailment, a greater need for effective long-term symptom management, broader availability of specialized gastrointestinal care, and the continuous requirement for enhanced motility-boosting treatments. Key developments expected in this period encompass an escalating dependence on prokinetic agents for managing symptoms, a rise in the application of combination drug therapies for gastroparesis, increasing requests for prescription-only gastroparesis medications, the proliferation of symptom-targeted treatment methodologies, and more widespread adoption of oral drug formulations for ongoing management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Key Drivers Are Affecting The Gastroparesis Drugs Market Development?

The rising incidence of diabetes is projected to fuel the expansion of the gastroparesis drugs market in the coming years. This condition is a long-term metabolic ailment marked by high blood glucose levels, which stem from either inadequate insulin generation or inefficient insulin use. Several factors contribute to the increasing occurrence of diabetes, including inactive lifestyles, poor eating habits, genetic susceptibility, urbanization, an aging demographic, and expanding obesity figures. The gastroparesis drugs market plays a role in diabetes management by offering medicines that alleviate symptoms like nausea, vomiting, and slow stomach emptying, which are frequent digestive issues linked with diabetic gastroparesis. For example, data released in March 2024 by the Office for Health Improvement & Disparities, a UK-based government department, indicated that from March 2022 to March 2023, the number of individuals with type 1 diabetes receiving all eight recommended care processes experienced a 22% rise. Concurrently, type 2 diabetes patients showed a 21% increase, and the proportion reaching target HbA1c levels climbed to 37.9%, representing the highest figure ever recorded by the National Diabetes Audit. Consequently, the growing incidence of diabetes is propelling the expansion of the gastroparesis drugs market.

How Are Segments Identified Within The Gastroparesis Drugs Market Segment Framework?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Which Trends Are Shaping Growth In The Gastroparesis Drugs Market?

Leading companies within the gastroparesis drugs market are concentrating on creating advanced solutions, including new prokinetic therapies, to enhance gastric motility and alleviate related symptoms. These novel prokinetic therapies represent fresh medications engineered to stimulate and boost the natural movement of the stomach and intestines, facilitating more efficient food passage. For example, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for the submission of Vanda’s New Drug Application (NDA) for tradipitant, intended for the management of gastroparesis symptoms. This specific approval concerns tradipitant, an investigational oral neurokinin-1 receptor antagonist, for addressing gastroparesis, which is a severe digestive ailment with significant unmet medical necessities. This acceptance represents a pivotal regulatory achievement for Vanda as the company proceeds with its efforts to gain marketing authorization for tradipitant in patients with gastroparesis.

Who Are The Companies Competing Within The Gastroparesis Drugs Market?

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

Get The Full Gastroparesis Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Which Region Is The Leading Market For The Gastroparesis Drugs Market?

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gastroparesis Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Browse Through More Reports Similar to the Global Gastroparesis Drugs Market 2026, By The Business Research Company

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Gastroparesis Drugs Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The gastroparesis drugs market size has demonstrated robust growth in recent years. It is forecast to rise from $5.7 billion in 2025 to $6.02 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.7%. This historical growth can be attributed to several factors, including the increasing diagnosis of diabetic gastroparesis, the longstanding application of prokinetic and antiemetic drugs, the growing prevalence of diabetes-related gastrointestinal disorders, the availability of both over-the-counter and prescription medications for symptom relief, and the expansion of gastroenterology care services.

The gastroparesis drugs market size is projected to experience robust expansion over the coming years. This market is anticipated to reach $7.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. Factors contributing to this growth during the projected timeframe include the increasing worldwide prevalence of diabetes, heightened recognition of gastroparesis as a chronic illness, a rising need for efficacious long-term symptom management, broader availability of specialized gastrointestinal treatment, and a continuous requirement for enhanced motility-improving therapies. Key developments expected within the forecast period involve an increased dependence on prokinetic agents for symptom relief, a surge in the adoption of combination drug therapies for gastroparesis, an escalating demand for prescription gastroparesis medications, an expansion of treatment strategies centered on symptoms, and a more widespread application of oral drug formulations for prolonged management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

What Drivers Are Influencing The Gastroparesis Drugs Market?

The increasing prevalence of diabetes is anticipated to propel the growth of the gastroparesis drugs market. Diabetes is a chronic metabolic disorder characterized by elevated blood sugar levels, resulting from inadequate insulin production or impaired insulin utilization. The rising occurrence of diabetes is attributed to factors such as sedentary lifestyles, unhealthy dietary behaviors, genetic predisposition, urbanization, aging populations, and growing obesity rates. The gastroparesis drugs market supports diabetes care by offering medications that relieve common gastrointestinal complications associated with diabetic gastroparesis, including symptoms like nausea, vomiting, and delayed gastric emptying. For instance, in March 2024, the Office for Health Improvement & Disparities, a UK-based government department, reported that between March 2022 and March 2023, individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while type 2 diabetes patients saw a 21% increase, and the percentage achieving target HbA1c levels rose to 37.9%, which was the highest value ever reported by the National Diabetes Audit. Therefore, the increasing prevalence of diabetes is driving the growth of the gastroparesis drugs market.

What Major Segment Divisions Exist Within The Gastroparesis Drugs Market?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

How Are Trends Shaping The Direction Of The Gastroparesis Drugs Market?

Leading companies in the gastroparesis drugs market are dedicated to developing groundbreaking solutions, such as novel prokinetic therapies, to enhance gastric motility and alleviate symptoms. These novel prokinetic therapies are new medications specifically designed to stimulate and improve the natural movement of the stomach and intestines, aiding in more effective food passage. For example, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for the submission of its New Drug Application (NDA) for tradipitant, aimed at treating symptoms of gastroparesis. This approval concerns tradipitant, an investigational oral neurokinin-1 receptor antagonist, intended to address gastroparesis, a severe digestive disorder with significant unmet medical needs. This acceptance represents a pivotal regulatory achievement for Vanda as it proceeds with its efforts to gain marketing authorization for tradipitant for patients suffering from gastroparesis.

Which Companies Are Leading Innovation In The Gastroparesis Drugs Market?

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

Read the full gastroparesis drugs market report here:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Gastroparesis Drugs Market?

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gastroparesis Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

Browse Through More Reports Similar to the Global Gastroparesis Drugs Market 2026, By The Business Research Company

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the gastroparesis drugs market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Gastroparesis Drugs Market?

The gastroparesis drugs market size has experienced significant expansion in recent years. This market is set to increase from $5.7 billion in 2025 to $6.02 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.7%. The market’s growth in the past can be attributed to factors such as the increasing diagnosis of diabetic gastroparesis, the long-standing use of prokinetic and antiemetic drugs, the growing prevalence of diabetes-related gastrointestinal disorders, the availability of both otc and prescription symptom relief medications, and the expansion of gastroenterology care services.

The gastroparesis drugs market is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $7.37 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. This projected growth during the forecast period stems from several factors, including the increasing worldwide prevalence of diabetes, heightened recognition of gastroparesis as a chronic ailment, a surging requirement for potent long-term symptom management, broader availability of specialized gastrointestinal care, and a continuous necessity for enhanced motility-improving therapies. Key trends expected during this period involve an increasing dependence on prokinetic agents for managing symptoms, a rise in the application of combination drug therapies for gastroparesis, a heightened call for prescription-only gastroparesis medications, the broadening of treatment strategies concentrated on specific symptoms, and a more extensive adoption of oral drug formulations for extended care.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Drivers Are Supporting The Rise Of The Gastroparesis Drugs Market?

The increasing prevalence of diabetes is anticipated to stimulate the expansion of the gastroparesis drugs market moving forward. Diabetes is a chronic metabolic condition defined by high blood sugar levels, which result from either insufficient insulin creation or impaired insulin use. The rise in diabetes cases is attributed to sedentary lifestyles, unhealthy dietary choices, genetic predispositions, increasing urbanization, aging populations, and rising obesity rates. The gastroparesis drugs market plays a crucial role in diabetes care by providing medications that mitigate symptoms like nausea, vomiting, and delayed gastric emptying, which are frequent gastrointestinal complications associated with diabetic gastroparesis. A notable example occurred in March 2024, when the Office for Health Improvement & Disparities, a UK-based government department, reported that from March 2022 to March 2023, the number of individuals with type 1 diabetes undergoing all eight recommended care processes increased by 22%, while for type 2 diabetes patients, there was a 21% rise, and the proportion achieving target HbA1c levels climbed to 37.9%, representing the highest figure ever recorded by the National Diabetes Audit. Therefore, the growing incidence of diabetes is indeed fostering the development of the gastroparesis drugs market.

What Leading Segments Are Studied In The Gastroparesis Drugs Market?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

What Trends Are Projected To Support The Growth Of The Gastroparesis Drugs Market?

Companies operating within the gastroparesis drugs market are actively developing innovative solutions, such as novel prokinetic therapies, to enhance gastric motility and alleviate symptoms. These new prokinetic therapies are medications designed to stimulate and improve the stomach and intestines’ normal movement, aiding more effective food passage. For example, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for the filing of its New Drug Application (NDA) for tradipitant, intended for treating gastroparesis symptoms. This approval concerns tradipitant, an investigational oral neurokinin-1 receptor antagonist, to address gastroparesis, a serious digestive disorder with significant unmet medical needs. This acceptance represents a crucial regulatory milestone for Vanda as it continues its efforts to secure marketing authorization for tradipitant for gastroparesis patients.

Which Leading Companies Dominate The Gastroparesis Drugs Market Share?

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

How Does The Gastroparesis Drugs Market Perform Across Major Global Regions?

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gastroparesis Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

Browse Through More Reports Similar to the Global Gastroparesis Drugs Market 2026, By The Business Research Company

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the respules market from 2025–2034 with trusted insights from The Business Research Company

What Is The Current Size And Expected Growth Outlook For The Respules Market?

The gastroparesis drugs market has experienced substantial expansion in recent years. This market is projected to expand from $5.39 billion in 2024 to $5.7 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 5.7%. Historically, this expansion has stemmed from factors such as side effects associated with current treatments, advancements in gastrointestinal motility research, unmet clinical needs, patient advocacy efforts, and supportive regulatory frameworks.

The gastroparesis drugs market is anticipated to experience robust expansion over the next few years, with projections indicating a rise to $7.04 billion in 2029, growing at a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period is primarily driven by the increasing prevalence of diabetes, an aging global population, heightened awareness and improved diagnosis rates, a surge in healthcare expenditure, and significant government and private funding. Furthermore, key trends influencing this period include advancements within gastroenterology, more refined diagnostic techniques, ongoing technological innovations, dedicated research funding, and various collaborative research endeavors.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Growth Drivers Are Propelling The Respules Market?

The rising incidence of diabetes is projected to fuel expansion within the gastroparesis drugs market moving forward. Diabetes is characterized as an ongoing health condition involving elevated blood sugar levels, resulting from insufficient insulin production or the body’s impaired response to insulin. This surge in diabetes cases is attributed to factors like inactive lifestyles, poor dietary choices, genetic susceptibility, increasing urbanization, and an aging global populace, further exacerbated by inadequate healthcare access and growing obesity rates. Medications for gastroparesis are commonly administered to diabetic individuals to ease symptoms such as nausea, vomiting, and slowed gastric emptying, which are frequent complications of diabetes impacting gastrointestinal movement. These treatments aim to optimize stomach function and improve the overall well-being for people experiencing gastroparesis linked to diabetes. A notable example from March 2024 indicates that, as reported by the Office for Health Improvement & Disparities, a UK-based government department, from March 2022 to March 2023, there was a 22% increase in the proportion of individuals with type 1 diabetes receiving all eight suggested care processes, and a 21% increase for those with type 2 diabetes. Additionally, the proportion achieving target HbA1c levels reached 37.9%, setting a new record according to the National Diabetes Audit (NDA). Consequently, the growing occurrence of diabetes is acting as a catalyst for the gastroparesis drugs market’s growth.

Which Segmentation Factors Are Most Significant In The Respules Market Analysis?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

What New Opportunities Are Emerging From Trends In The Respules Market?

Major companies active in the gastroparesis drugs market are prioritizing the introduction of innovative medications, exemplified by Gimoti (metoclopramide) nasal spray, to secure a competitive advantage. Gimoti (metoclopramide) nasal spray is a treatment designed to manage gastroparesis symptoms in adults, facilitating stomach emptying by improving gastrointestinal motility. This medication uniquely bypasses the gastrointestinal tract, achieving direct absorption into the bloodstream through the nasal mucosa. For instance, in April 2022, Evoke Pharma Inc., a US-based pharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) had awarded new drug product exclusivity for GIMOTI (metoclopramide) nasal spray. This exclusivity grants Evoke sole marketing rights for three years from the original approval date under the Hatch-Waxman Act, safeguarding the product from generic competition.

Who Are The Most Influential Companies In The Respules Market?

Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Which Region Holds The Largest Share In The Respules Market Today?

North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

Browse Through More Reports Similar to the Global Respules Market 2025, By The Business Research Company

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Insulin Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Fertility Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/fertility-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Are The Future Growth Projections For The Gastroparesis Drugs Market Size?

Over recent years, the market size for drugs used to treat gastroparesis has seen significant growth. Its size is projected to increase from $5.39 billion in 2024 to $5.7 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. Factors that contributed to this development during the historic period include side effects from current treatments, studies into gastrointestinal motility, clinical demand, patient advocacy efforts, and assistance from regulatory bodies.

In the coming years, the market for gastroparesis drugs is projected to experience significant expansion, with an anticipated value of $7.04 billion by 2029, manifesting a compound annual growth rate (CAGR) of 5.4%. Factors contributing to this anticipated growth within the forecast period include increasing incidences of diabetes, an aging demographic, heightened awareness and diagnostic rates, amplified expenditure in healthcare, and support from private and government sectors. Key advancements expected over the forecast period encompass progress in gastroenterology, enhanced diagnostic methods, technological breakthroughs, increased research funding and collaborative research initiatives.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Key Factors Are Fueling Growth In The Gastroparesis Drugs Market?

Rising instances of diabetes are predicted to drive the expansion of the gastroparesis drugs market. Known as a recurrent health concern characterized by heightened sugar levels in the blood due to inefficient insulin production or use, the escalating occurrence of diabetes can be attributed to inactive lifestyles, poor eating habits, genetic factors, urbanization, and an aging global population. This is further exacerbated by insufficient access to healthcare and increasing global obesity. Gastroparesis medications are regularly given to diabetics to relieve symptoms such as nausea, vomiting, and the slowing of gastric emptying, all typical diabetes-related issues influencing gastrointestinal mobility. These drugs aim to enhance gastric function and improve the life quality of patients suffering from diabetes-induced gastroparesis. For example, March 2024 data from the Office for Health Improvement & Disparities, a UK government department show that the proportion of individuals with type 1 diabetes undergoing all eight recommended care processes saw a 22% boost, while for type 2 diabetes the increase was 21% from March 2022 to March 2023. Moreover, the percentage achieving the target HbA1c levels hit 37.9%, the highest figure ever reported by the National Diabetes Audit (NDA). Hence, the rising prevalence of diabetes further propels the gastroparesis drugs market.

How Is The Gastroparesis Drugs Market Categorized Across Applications And Types?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

How Are Market Trends Influencing Competition In The Gastroparesis Drugs Market?

Leading firms in the gastroparesis drugs market are concentrating on developing and introducing innovative medication such as Gimoti (metoclopramide) nasal spray to gain a market advantage. Gimoti (metoclopramide) nasal spray, designed for adult gastroparesis symptom treatment, aids in stomach emptying by boosting gastrointestinal mobility. This drug avoids the gastrointestinal tract and is directly absorbed into the blood via the nasal mucosa. For instance, in April 2022, Evoke Pharma Inc., a pharmaceutical organization based in the USA, confirmed the FDA’s grant of new product exclusivity for GIMOTI (metoclopramide) nasal spray. This exclusivity provides Evoke with the sole distribution rights for three years from the initial approval date according to the Hatch-Waxman Act, safeguarding the product from any generic competition.

Who Are The Most Influential Companies In The Gastroparesis Drugs Market?

Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Which Region Holds The Greatest Opportunity For Gastroparesis Drugs Market Expansion?

North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model